Ignite Creation Date:
2024-05-06 @ 2:53 AM
Last Modification Date:
2024-10-26 @ 11:25 AM
Study NCT ID:
NCT02151747
Status:
COMPLETED
Last Update Posted:
2019-10-07
First Post:
2014-05-28
Brief Title:
Testing BRCA 12 Mutation Using Next Generation Sequencing
Sponsor:
Severance Hospital
Organization:
Severance Hospital
Study Overview
Official Title:
Pilot Study of Validation of Testing BRCA 12 Mutation Using Next Generation Sequencing
Status:
COMPLETED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRCANGS
Brief Summary:
Testing BRCA 12 mutation is important for patients with breast cancer and Sanger sequencing is a standard method to identify BRCA 12 mutation Next generation sequencing NGS is a high-throughput parallel sequencing that can provide genetic information with high accuracy NGS is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing In this study we evaluated the clinical role of NGS testing for BRCA 12 compared to Sanger sequencing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None